<DOC>
	<DOCNO>NCT03000075</DOCNO>
	<brief_summary>This randomize double blind , double dummy , placebo control , parallel design study perform assess safety efficacy BI 655066 ( risankizumab ) .</brief_summary>
	<brief_title>BI 655066 ( Risankizumab ) Compared Placebo Japanese Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have diagnosis chronic plaque psoriasis ( without psoriatic arthritis ) least 6 month first administration study drug . Duration diagnosis may report patient . Have stable moderate severe chronic plaque psoriasis without psoriatic arthritis Screening Baseline ( Randomisation ) : 1 . Have involve BSA ≥10 % 2 . Have PASI score ≥12 3 . Have sPGA score ≥3 . Patients 1. nonplaque form psoriasis ( include guttate , erythrodermic , pustular ) 2. current druginduced psoriasis ( include exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) 3. active ongoing inflammatory disease psoriasis psoriatic arthritis might confound trial evaluation accord investigator 's judgment Previous exposure BI 655066</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BI 655066</keyword>
	<keyword>ABBV-066</keyword>
	<keyword>risankizumab</keyword>
</DOC>